Go Deep
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,646 | -2.2 | 1.00 | 0.18 | 159.99 |
| Oct 2026 | 21,620 | -2.3 | 1.01 | 0.18 | 161.41 |
| Oct 2026 | 21,568 | -2.3 | 1.04 | 0.18 | 165.23 |
| Oct 2026 | 21,594 | -2.3 | 1.03 | 0.18 | 162.91 |
| Oct 2026 | 21,476 | -2.4 | 1.08 | 0.18 | 171.62 |
| Oct 2026 | 21,135 | -2.8 | 1.23 | 0.18 | 196.27 |
| Oct 2026 | 21,122 | -2.8 | 1.24 | 0.18 | 196.73 |
| Oct 2026 | 21,122 | -2.8 | 1.24 | 0.18 | 196.33 |
Black Diamond Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -9,905,000.0 | -9,036,000.0 | -15,116,000.0 | -8,498,000.0 |
| EPS | -0.2 | -0.2 | -0.3 | -0.1 |
Black Diamond Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 70,000,000.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | 22,367,000.0 | -69,676,000.0 | -82,442,000.0 | -91,169,000.0 | — |
| EPS | 0.4 | -1.3 | -1.9 | -2.5 | — |
Black Diamond Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 143,010,000.0 | 122,640,000.0 | 158,567,000.0 | 156,255,000.0 | — |
| Total Liabilities | 30,799,000.0 | 39,355,000.0 | 41,831,000.0 | 40,560,000.0 | — |
| Total Equity | 112,211,000.0 | 83,285,000.0 | 116,736,000.0 | 115,695,000.0 | — |
Owes vs Owns
Black Diamond Therapeutics, Inc. owed $0.23 for every $1 it owned in Jun 2026, down from $0.26 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.23× | 0.22× | 0.32× | 0.26× | 0.26× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Black Diamond Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 90.0%Fixed assets (tangible) 6.8%Other assets 3.3%
How it's funded — Dec 2025
Short-term debt 2.6%Long-term debt 10.5%Other liabilities 8.0%Shareholders' equity 78.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 128.7 | 98.6 | 131.4 | 122.8 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 9.7 | 20.4 | 23.7 | 27.4 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 4.7 | 3.7 | 3.5 | 6.1 |
| Liabilities & equity | ||||
| Short-term debt | 3.7 | 3.4 | 3.1 | 2.8 |
| Long-term debt | 15.1 | 18.8 | 22.2 | 25.3 |
| Payables | 0.6 | 4.0 | 2.3 | 1.9 |
| Other liabilities | 11.4 | 13.2 | 14.2 | 10.5 |
| Shareholders' equity | 112.2 | 83.3 | 116.7 | 115.7 |
| Net tangible assets | 112.2 | 83.3 | 116.7 | 115.7 |
Black Diamond Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 29,614,000.0 | -62,303,000.0 | -66,717,000.0 | -85,082,000.0 | — |
| Investing Activities | -44,905,000.0 | 16,968,000.0 | 16,346,000.0 | 53,366,000.0 | — |
| Financing Activities | -146,000.0 | 25,547,000.0 | 71,932,000.0 | 177,000.0 | — |